Publications by authors named "Shumaila Sultan"
The novel coronavirus outbreak of SARS-CoV-2 first began in Wuhan, China, in December 2019. The most striking manifestation of SARS-CoV-2 is atypical pneumonia and respiratory complications; however, various neurological manifestations are now well recognized. Currently, there have been very few case reports regarding COVID-19 in patients with a known history of myasthenia gravis.
View Article and Find Full Text PDFA Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of In Patients With ALS.
Amyotroph Lateral Scler Frontotemporal Degener
May 2021
Article Synopsis
- A study was conducted to assess the safety, dose response, and initial efficacy of a treatment for patients with amyotrophic lateral sclerosis (ALS) over 12 weeks.
- A total of 458 patients were enrolled, with results showing no significant improvements in the primary endpoint of slow upright vital capacity (SVC) or secondary measures like the ALS Functional Rating Scale and muscle strength mega-score during the 12 weeks.
- While the main analysis did not reach statistical significance, trends indicated potential benefits for active treatment compared to placebo, and the treatment was generally well tolerated, with minor side effects and reversible liver and kidney issues noted.